Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin

Stephen Williams, Ashish M. Kamat, Chinedu Mmeje, Yuanquing Ye, Maosheng Huang, David W. Chang, Colin P. Dinney, Xifeng Wu

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Inflammation plays a critical role in the etiology of several cancers and may affect their clinical outcome. Our objective was to assess the association of genetic variants within the inflammation pathway with recurrence and progression among non-muscle invasive bladder cancer (NMIBC) patients with or without Bacillus Calmette-Guérin (BCG) treatment. We genotyped 372 single nucleotide polymorphisms (SNPs) in 27 selected genes within the inflammation pathway in 349 patients diagnosed with NMIBC, followed by internal validation in 322 additional patients. We used Cox proportional hazards regression analyses to identify SNPs as predictors for recurrence and progression. In the discovery phase, we identified 20 variants that were significantly associated with recurrence outcomes and 15 SNPs significantly associated with progression in patients treated with BCG but not in the transurethral resection (TUR)-only group. In BCG treated patients, rs7089861 was the only SNP significantly associated with risk of progression in both the discovery phase (Hazard Ratio [HR]=3.15, 95% Confidence Interval [CI]: 1.38-7.22, P < 0.01) and validation phase (HR=3.84, 95% CI: 1.64-9.0, P=0.002; meta-analysis HR=3.47, 95% CI: 1.92-6.28, P < 0.001). Two variants, rs1800686 and rs2071081, had probable association with HRs of the same trend in the discovery and validation groups (metaanalysis P=0.002). These findings supported the notion that genetic variation of inflammation pathway may impact clinical outcome of NMIBC patients treated with BCG immunotherapy. Further validation of these results in order to improve risk stratification to identify patients most likely to benefit from BCG treatment versus upfront radical cystectomy and future development of potential targeted therapies are warranted. Significance Statement: In a two-stage study, we identified several genetic variants in the inflammation pathway associated with recurrence and progression in early-stage bladder cancer. In particular, variant rs7089861 was validated for progression among patients who underwent BCG immunotherapy. Several other variants showed marginal association with recurrence or progression. These findings suggest that inflammatory pathway genetic variants may influence clinical outcome of bladder cancer patients and help to select patients most appropriate for BCG treatment.

    Original languageEnglish (US)
    Pages (from-to)88782-88791
    Number of pages10
    JournalOncotarget
    Volume8
    Issue number51
    DOIs
    StatePublished - 2017

    Fingerprint

    Urinary Bladder Neoplasms
    Bacillus
    Inflammation
    Recurrence
    Single Nucleotide Polymorphism
    Confidence Intervals
    Immunotherapy
    Cystectomy
    Therapeutics
    Meta-Analysis
    Regression Analysis

    Keywords

    • BCG
    • Bladder cancer
    • Clinical outcome
    • Inflammation
    • Polymorphisms

    ASJC Scopus subject areas

    • Oncology

    Cite this

    Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin. / Williams, Stephen; Kamat, Ashish M.; Mmeje, Chinedu; Ye, Yuanquing; Huang, Maosheng; Chang, David W.; Dinney, Colin P.; Wu, Xifeng.

    In: Oncotarget, Vol. 8, No. 51, 2017, p. 88782-88791.

    Research output: Contribution to journalArticle

    Williams, Stephen ; Kamat, Ashish M. ; Mmeje, Chinedu ; Ye, Yuanquing ; Huang, Maosheng ; Chang, David W. ; Dinney, Colin P. ; Wu, Xifeng. / Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin. In: Oncotarget. 2017 ; Vol. 8, No. 51. pp. 88782-88791.
    @article{5e30ee3a8c36455eb7f3be673b8a620c,
    title = "Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Gu{\'e}rin",
    abstract = "Inflammation plays a critical role in the etiology of several cancers and may affect their clinical outcome. Our objective was to assess the association of genetic variants within the inflammation pathway with recurrence and progression among non-muscle invasive bladder cancer (NMIBC) patients with or without Bacillus Calmette-Gu{\'e}rin (BCG) treatment. We genotyped 372 single nucleotide polymorphisms (SNPs) in 27 selected genes within the inflammation pathway in 349 patients diagnosed with NMIBC, followed by internal validation in 322 additional patients. We used Cox proportional hazards regression analyses to identify SNPs as predictors for recurrence and progression. In the discovery phase, we identified 20 variants that were significantly associated with recurrence outcomes and 15 SNPs significantly associated with progression in patients treated with BCG but not in the transurethral resection (TUR)-only group. In BCG treated patients, rs7089861 was the only SNP significantly associated with risk of progression in both the discovery phase (Hazard Ratio [HR]=3.15, 95{\%} Confidence Interval [CI]: 1.38-7.22, P < 0.01) and validation phase (HR=3.84, 95{\%} CI: 1.64-9.0, P=0.002; meta-analysis HR=3.47, 95{\%} CI: 1.92-6.28, P < 0.001). Two variants, rs1800686 and rs2071081, had probable association with HRs of the same trend in the discovery and validation groups (metaanalysis P=0.002). These findings supported the notion that genetic variation of inflammation pathway may impact clinical outcome of NMIBC patients treated with BCG immunotherapy. Further validation of these results in order to improve risk stratification to identify patients most likely to benefit from BCG treatment versus upfront radical cystectomy and future development of potential targeted therapies are warranted. Significance Statement: In a two-stage study, we identified several genetic variants in the inflammation pathway associated with recurrence and progression in early-stage bladder cancer. In particular, variant rs7089861 was validated for progression among patients who underwent BCG immunotherapy. Several other variants showed marginal association with recurrence or progression. These findings suggest that inflammatory pathway genetic variants may influence clinical outcome of bladder cancer patients and help to select patients most appropriate for BCG treatment.",
    keywords = "BCG, Bladder cancer, Clinical outcome, Inflammation, Polymorphisms",
    author = "Stephen Williams and Kamat, {Ashish M.} and Chinedu Mmeje and Yuanquing Ye and Maosheng Huang and Chang, {David W.} and Dinney, {Colin P.} and Xifeng Wu",
    year = "2017",
    doi = "10.18632/oncotarget.21222",
    language = "English (US)",
    volume = "8",
    pages = "88782--88791",
    journal = "Oncotarget",
    issn = "1949-2553",
    publisher = "Impact Journals",
    number = "51",

    }

    TY - JOUR

    T1 - Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin

    AU - Williams, Stephen

    AU - Kamat, Ashish M.

    AU - Mmeje, Chinedu

    AU - Ye, Yuanquing

    AU - Huang, Maosheng

    AU - Chang, David W.

    AU - Dinney, Colin P.

    AU - Wu, Xifeng

    PY - 2017

    Y1 - 2017

    N2 - Inflammation plays a critical role in the etiology of several cancers and may affect their clinical outcome. Our objective was to assess the association of genetic variants within the inflammation pathway with recurrence and progression among non-muscle invasive bladder cancer (NMIBC) patients with or without Bacillus Calmette-Guérin (BCG) treatment. We genotyped 372 single nucleotide polymorphisms (SNPs) in 27 selected genes within the inflammation pathway in 349 patients diagnosed with NMIBC, followed by internal validation in 322 additional patients. We used Cox proportional hazards regression analyses to identify SNPs as predictors for recurrence and progression. In the discovery phase, we identified 20 variants that were significantly associated with recurrence outcomes and 15 SNPs significantly associated with progression in patients treated with BCG but not in the transurethral resection (TUR)-only group. In BCG treated patients, rs7089861 was the only SNP significantly associated with risk of progression in both the discovery phase (Hazard Ratio [HR]=3.15, 95% Confidence Interval [CI]: 1.38-7.22, P < 0.01) and validation phase (HR=3.84, 95% CI: 1.64-9.0, P=0.002; meta-analysis HR=3.47, 95% CI: 1.92-6.28, P < 0.001). Two variants, rs1800686 and rs2071081, had probable association with HRs of the same trend in the discovery and validation groups (metaanalysis P=0.002). These findings supported the notion that genetic variation of inflammation pathway may impact clinical outcome of NMIBC patients treated with BCG immunotherapy. Further validation of these results in order to improve risk stratification to identify patients most likely to benefit from BCG treatment versus upfront radical cystectomy and future development of potential targeted therapies are warranted. Significance Statement: In a two-stage study, we identified several genetic variants in the inflammation pathway associated with recurrence and progression in early-stage bladder cancer. In particular, variant rs7089861 was validated for progression among patients who underwent BCG immunotherapy. Several other variants showed marginal association with recurrence or progression. These findings suggest that inflammatory pathway genetic variants may influence clinical outcome of bladder cancer patients and help to select patients most appropriate for BCG treatment.

    AB - Inflammation plays a critical role in the etiology of several cancers and may affect their clinical outcome. Our objective was to assess the association of genetic variants within the inflammation pathway with recurrence and progression among non-muscle invasive bladder cancer (NMIBC) patients with or without Bacillus Calmette-Guérin (BCG) treatment. We genotyped 372 single nucleotide polymorphisms (SNPs) in 27 selected genes within the inflammation pathway in 349 patients diagnosed with NMIBC, followed by internal validation in 322 additional patients. We used Cox proportional hazards regression analyses to identify SNPs as predictors for recurrence and progression. In the discovery phase, we identified 20 variants that were significantly associated with recurrence outcomes and 15 SNPs significantly associated with progression in patients treated with BCG but not in the transurethral resection (TUR)-only group. In BCG treated patients, rs7089861 was the only SNP significantly associated with risk of progression in both the discovery phase (Hazard Ratio [HR]=3.15, 95% Confidence Interval [CI]: 1.38-7.22, P < 0.01) and validation phase (HR=3.84, 95% CI: 1.64-9.0, P=0.002; meta-analysis HR=3.47, 95% CI: 1.92-6.28, P < 0.001). Two variants, rs1800686 and rs2071081, had probable association with HRs of the same trend in the discovery and validation groups (metaanalysis P=0.002). These findings supported the notion that genetic variation of inflammation pathway may impact clinical outcome of NMIBC patients treated with BCG immunotherapy. Further validation of these results in order to improve risk stratification to identify patients most likely to benefit from BCG treatment versus upfront radical cystectomy and future development of potential targeted therapies are warranted. Significance Statement: In a two-stage study, we identified several genetic variants in the inflammation pathway associated with recurrence and progression in early-stage bladder cancer. In particular, variant rs7089861 was validated for progression among patients who underwent BCG immunotherapy. Several other variants showed marginal association with recurrence or progression. These findings suggest that inflammatory pathway genetic variants may influence clinical outcome of bladder cancer patients and help to select patients most appropriate for BCG treatment.

    KW - BCG

    KW - Bladder cancer

    KW - Clinical outcome

    KW - Inflammation

    KW - Polymorphisms

    UR - http://www.scopus.com/inward/record.url?scp=85031921618&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85031921618&partnerID=8YFLogxK

    U2 - 10.18632/oncotarget.21222

    DO - 10.18632/oncotarget.21222

    M3 - Article

    VL - 8

    SP - 88782

    EP - 88791

    JO - Oncotarget

    JF - Oncotarget

    SN - 1949-2553

    IS - 51

    ER -